Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Serlopitant
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant
Details : Study MTI-105 and Study MTI-106 did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 04, 2020
Lead Product(s) : Serlopitant
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AMZEEQ® (minocycline) topical foam, 4%, for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients, has been added to the prescription drug formulary of one of the largest payors in the U.S...
Product Name : Amzeeq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 27, 2020
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Minocycline Hydrochloride,Adapalene
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FCD105 showed a highly statistically significant improvement compared to vehicle for the endpoints of Investigator’s Global Assessment treatment success and absolute change from baseline in mean inflammatory counts at Week 12.
Product Name : Amzeeq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 06, 2020
Lead Product(s) : Minocycline Hydrochloride,Adapalene
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable